Trials / Withdrawn
WithdrawnNCT02269579
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CPX-351 |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2014-10-21
- Last updated
- 2018-03-14
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02269579. Inclusion in this directory is not an endorsement.